Two of the world’s largest publicly-traded tobacco companies — British American Tobacco (BAT) and Philip Morris International (Philip Morris) — are exploiting the popularity of social media to market addictive products to young people.
[{{{type}}}] {{{reason}}}
{{/data.error.root_cause}}{{{_source.displayDate}}}
{{/_source.showDate}}{{{_source.description}}}
{{#_source.additionalInfo}}{{#_source.additionalFields}} {{#title}} {{{label}}}: {{{title}}} {{/title}} {{/_source.additionalFields}}
{{/_source.additionalInfo}}Aussie drink-driving laws have similar penalties, but our BAC level is still at .05. This will be moved to .02 in the coming years.
Be safe for you, your family and the person you may injure because, you thought you were ‘ok to drive!’
SHOULD YOU BE DRIVING? DON'T DRINK AND DRIVE....EVER!
TEST YOURSELF NOW
Did you get your copy of the
FenceBuilder Newsletter?
Two of the world’s largest publicly-traded tobacco companies — British American Tobacco (BAT) and Philip Morris International (Philip Morris) — are exploiting the popularity of social media to market addictive products to young people.
A critique by Neil O’Connell of Brunel University London found that 10 studies led by Marco Monticone of Italy’s University of Cagliari in Italy had inconsistencies including data that diverged from almost all similar studies, impossible statistical significance values, and duplicate or very similar data.
Also see
The length of stay in intensive care varies greatly, from a few days up to a month. When taken home, for several months these babies may still experience signs of withdrawal.
This baby had tense and clenched muscles. She could not organise a suck pattern to feed effectively and required a feeding tube, and she would tremor and jerk so much she rubbed her chin raw on her blankets.
The nurses would take turns swaying and rocking with her for hours. This baby was medicated with morphine and gas drops, and was tried on multiple different formulas to help try to soothe her and settle her reflux.
Often it is the case that mothers with drug dependence really want to get off drugs and care for their baby. They love their children, but the truth is that their addiction has a strong hold on them. (for complete article https://newsweekly.com.au/newsweekly/addictions-littlest-victims/)
Also see
Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial.
Background: Painful knee osteoarthritis (KOA) is common, pharmacological treatment, however, is often hampered by limited tolerability. Cannabidiol, which preclinically showed anti-inflammatory, analgesic activity, could supplement established analgesics, but robust clinical trials are lacking. The aim of our study was to investigate the effects of oral high-dose CBD administered over 8 weeks on pain, function and patient global assessment as an add-on to continued paracetamol in chronic symptomatic KOA.
Methods: Prospective, randomized, placebo-controlled, double-blind, parallel-group study. Single center, Outpatient Clinic, Department of Special Anaesthesia and Pain Therapy at Medical University of Vienna, Austria. Eligibility criteria included: age: 18–98 years; painful KOA; score ≥5 on the pain subscale of the Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Index; KOA confirmed by imaging. Participants were on continued dosage of paracetamol 3 g/d and randomly assigned by web-based software 1:1 to oral cannabidiol 600 mg/d (n = 43) or placebo (n = 43). Study period: 8 weeks. Primary outcome: Change in WOMAC pain subscale scores (0 = no pain, 10 = worst possible pain) from baseline to week 8 of treatment. Trial Registration: ClinicalTrials.gov Identifier: NCT04607603. Trial is completed.
Interpretation: In KOA patients, oral high-dose add-on cannabidiol had no additional analgesic effect compared to adding placebo to continued paracetamol. Our results do not support the use of cannabidiol as an analgesic supplement in KOA
(Source: https://www.sciencedirect.com/science/article/pii/S2666776223001965 )
Also see
Published: October 18, 202 3DOI:https://doi.org/10.1016/j.jpain.2023.10.009
Highlights
Small clinical trials using verified CBD suggest the drug to be largely benign; while large scale evidence of safety is lacking there is growing evidence linking CBD to increased rates of serious adverse events and hepatotoxicity.
There is no good reason for thinking that CBD relieves pain, but there are good reasons for doubting the contents of CBD products in terms of CBD content and purity.
(for complete research The Journal of Pain – (US Association for Study of Pain, USASP)
Also see
Page 18 of 103
[{{{type}}}] {{{reason}}}
{{/data.error.root_cause}}{{{_source.displayDate}}}
{{/_source.showDate}}{{{_source.description}}}
{{#_source.additionalInfo}}{{#_source.additionalFields}} {{#title}} {{{label}}}: {{{title}}} {{/title}} {{/_source.additionalFields}}
{{/_source.additionalInfo}}